Table 4.
Clinical data of published randomized controlled trials
| Research | ORIENT-11 | CheckMate 227 | CameL-Sq | Rationale 307 | IMpower150 | ONO-4538-52/TASUKI-52 |
|---|---|---|---|---|---|---|
| PD-1/PD-L1 combined with chemotherapy | Sintilimab | Nivolumab | Camrelizumab | Tislelizumab | - | - |
| Anti-angiogenesis plus PD-1/PD-L1 plus chemotherapy | - | - | - | - | Bevacizumab plus atezolizumab | Bevacizumab plus nivolumab |
| Phase | III | III | III | III | III | III |
| Number of patients in the study group | 266 | 377 | 193 | 120/119* | 356 | 273 |
| Primary endpoint | PFS, OS | OS | PFS | PFS | PFS, OS | PFS |
| Median PFS (months) | 8.9 | 8.4 | 8.5 | 7.6 | 8.3 | 12.1 |
| Median OS (months) | 24.2 | 18.3 | NR | NR | 19.5 | 25.4 |
| ORR (%) | 51.9 | 51.5 | 64.8 | 72.5/74.8 | 64 | 61.5 |
| References | Yang et al. [12, 17] | Paz-Ares et al. [16] | Ren et al. [14] | Wang et al. [15] | Socinski et al. [35, 36] | Sugawara et al. [37] |
PFS, progression-free survival; OS, overall survival; ORR, objective response rate; NR, not reached; *, arm A included 120 patients receiving tislelizumab plus paclitaxel and arm B included 119 patients receiving tislelizumab plus nab-paclitaxel